Pestalozzi advises Promethera Biosciences SA in connection with its acquisition of Baliopharm AG
On 10 April 2018, Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases based in Mont-Saint-Guibert, Belgium, announced that it has acquired Baliopharm AG, a Swiss biopharmaceutical company focused on the development of targeted biological therapies for immune mediated inflammatory diseseas and cancer. Pestalozzi advised Promethera on Swiss law aspects of this transaction.